Cellectis (CLLS) Cash from Investing Activities (2015 - 2026)

Cellectis' (CLLS) quarterly Cash from Investing Activities came in at -$6.2 million in Q1 2026, down 245.99% year-on-year from $4.2 million in Q1 2025, and down 127.46% quarter-over-quarter from $22.5 million in Q4 2025.

Cellectis (CLLS) Cash from Investing Activities (2015 - 2026) Analysis & Trends

Cellectis' Cash from Investing Activities history runs 12 years deep, the most recent figure standing at -$6.2 million for Q1 2026.

  • On a quarterly basis, Cash from Investing Activities fell 245.99% year-over-year to -$6.2 million in Q1 2026; TTM through Mar 2026 was -$39.9 million, a 58.7% increase from a year earlier, with the FY2025 full-year figure at -$29.5 million, up 71.32% from the prior year.
  • Cash from Investing Activities eased to -$6.2 million in Q1 2026 per CLLS's latest filing, from $22.5 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $22.5 million in Q4 2025 and bottomed at -$106.4 million in Q2 2024.
  • The 5-year median for Cash from Investing Activities is -$1.1 million (2022), against an average of -$9.2 million.
  • Biggest YoY gain for Cash from Investing Activities was 7544.33% in 2024; the steepest drop was 5916.34% in 2024.
  • Year by year, Cash from Investing Activities stood at -$730000.0 in 2022, then plunged by 1770.27% to -$13.7 million in 2023, then decreased by 22.03% to -$16.7 million in 2024, then soared by 234.75% to $22.5 million in 2025, then slumped by 127.46% to -$6.2 million in 2026.
  • Per Business Quant, the three latest CLLS Cash from Investing Activities figures stand at -$6.2 million (Q1 2026), $22.5 million (Q4 2025), and -$3.4 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Oculis Holding AG 66,741.39 Bn 66,741.11 Bn - -
2 Nanobiotix 1,912.31 Bn 1,912.25 Bn - -
3 Akari Therapeutics 1,009.43 Bn 1,009.43 Bn - -
4 BeOne Medicines 467.15 Bn 462.36 Bn 1.35 Bn -45.51 Mn
5 Vertex Pharmaceuticals 123.00 Bn 115.76 Bn 2.59 Bn -431.90 Mn
6 Regeneron Pharmaceuticals 70.22 Bn 61.47 Bn 3.31 Bn -428.90 Mn
7 Belite Bio 62.93 Bn 62.93 Bn - -
8 Argenx Se 55.76 Bn 50.57 Bn 1.41 Bn -
9 Alnylam Pharmaceuticals 37.70 Bn 34.69 Bn 959.66 Mn -25.54 Mn
10 Cellectis 290.61 Mn 104.95 Mn - -6.17 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -6.17 Mn
Mar 31, 2026 -6.17 Mn
Dec 31, 2025 22.45 Mn
Dec 31, 2025 22.45 Mn
Sep 30, 2025 -3.44 Mn
Sep 30, 2025 -3.44 Mn
Jun 30, 2025 -52.72 Mn
Jun 30, 2025 -52.72 Mn
Mar 31, 2025 4.22 Mn
Mar 31, 2025 4.22 Mn
Dec 31, 2024 -16.66 Mn
Dec 31, 2024 -16.66 Mn
Sep 30, 2024 22.33 Mn
Sep 30, 2024 22.33 Mn
Jun 30, 2024 -106.43 Mn
Jun 30, 2024 -106.43 Mn
Mar 31, 2024 -2.05 Mn
Mar 31, 2024 -2.05 Mn
Dec 31, 2023 -13.65 Mn
Dec 31, 2023 -13.65 Mn